| N = 12 |
---|---|
Median Age at treatment start, years (range) | 60 (47–84) |
Gender, n (%) | |
 Men  Women | 8 (67) 4 (33) |
Ethnicity, n (%) | |
  Caucasian   Asian   Black | 9 (75) 2 (16) 1 (9) |
Stage at Diagnosis, n (%) | |
  IVA   IVB   IVC | 0 (0) 3 (25) 9 (75) |
Pathology, n (%) | |
  ATC only   Papillary thyroid cancer + ATC   Poorly differentiated thyroid cancer + ATC   Follicular thyroid cancer +ATC | 4 (33) 4 (33) 3 (25) 1 (9) |
PD-L1 status, n (%)   < 10%  11–50%  51–100% | 10 (83) 2 (20) 4 (40) 4 (40) |
Performance Status, n (%) | |
  ECOG 0   ECOG 1   ECOG 2 | 2 (16) 6 (50) 4 (33) |
Previous Treatment for ATC, n (%)a | |
  Surgery, n (%)   Radiation/chemosensitizing, n (%)   Bridging Chemotherapy, n (%)b | 5 (41) 6 (50) 3 (25) |
Targeted therapyc, n (%) | |
  Lenvatinib   Dabrafenib + trametinib   Trametinib alone | 5 (41) 6 (50) 1 (9) |